Amylyx Pharmaceuticals (AMLX) shares fell over 3% on Thursday to $13.59 as the market struggled to identify a specific immediate trigger for the decline. This move extends a recent downward trend, with the stock dropping over 8% in the past five trading days.
| Current Price | $13.59 |
| Daily Change | -3.41% 🔴 |
| Day Range | $13.26 – $14.24 |
| 5-Day Performance | -8.29% 🔴 |
| Jan 14 Close | $14.07 |
The current volatility comes despite a lack of fresh regulatory or clinical updates within the last 48 hours. Market data shows that AMLX closed at $14.07 on January 14, 2026, before slipping further during today's session.
While today's movement is relatively contained, it reminds investors of the stock's historically volatile nature. Amylyx has experienced massive swings in the past year, largely linked to clinical trial results and capital raising activities.
Key Takeaways
- AMLX stock dropped 3.4% today to $13.59 without a clear immediate catalyst.
- The stock has declined over 8% over the last five trading days.
- Amylyx is slightly underperforming the broader biotechnology sector's 3.3% decline.
- Recent history includes a $175 million public offering and a major Phase 3 trial failure for its drug Relyvrio.
- Analyst sentiment remains split, with price targets ranging from $5 to $20.
Why Did Amylyx Pharmaceuticals (AMLX) Stock Drop 3.41% Today?
Financial analysts have not identified a specific event or news release to explain today's 3.4% drop. The decline appears to be part of a broader correction after the stock's significant performance gains over the last year.
According to historical market data, the stock is still up more than 331% over the past 12 months. This long-term rally may be prompting some investors to take profits in the absence of new positive news.
The trading range today remained between $13.26 and $14.24. Without a company announcement, the move suggests a technical or sentiment-driven shift rather than a fundamental change in the company's prospects.
How Does AMLX Compare to the Biotechnology Sector Today?
The broader biotechnology industry is facing headwinds today, with the sector seeing an average decline of nearly 3.3%. Amylyx's drop of 3.4% indicates it is slightly underperforming its industry peers.
Specific peer comparisons show mixed results across the sector. For instance, MarketBeat data indicates that while RAPT Therapeutics fell 6% and Anbio Biotechnology dropped nearly 7.7%, other firms like Structure Therapeutics remained flat.
| Company | Symbol | Daily Change |
|---|---|---|
| Structure Therapeutics Inc. | GPCR | +0.04% 🟢 |
| Inhibrx Biosciences, Inc. | INBX | -3.07% 🔴 |
| RAPT Therapeutics, Inc. | RAPT | -6.00% 🔴 |
| Anbio Biotechnology | NNNN | -7.70% 🔴 |
| Celldex Therapeutics, Inc. | CLDX | -3.30% 🔴 |
| Industry Average | – | -3.29% |
| Amylyx Pharma | AMLX | -3.41% 🔴 |
Other notable peers also saw declines, including Celldex Therapeutics at 3.3% and Inhibrx Biosciences at roughly 3.1%. Amylyx remains more volatile than many of its larger counterparts in the biotechnology space.
Recent Milestones: Public Offering and Shifting Analyst Outlook
In late 2025, Amylyx bolstered its balance sheet through a substantial underwritten public offering. The company priced 17.5 million shares at $10.00 each, generating approximately $175 million in gross proceeds.
According to reports from Investing.com, the funds were earmarked for the commercial readiness of Avexitide and general research and development. While the offering signaled potential share dilution, it provided a significant capital cushion for the firm.
Analyst responses to these milestones have been varied. On November 10, 2025, H.C. Wainwright raised its price target for AMLX to $20.00.
Many investors track such upgrades via stock analysis apps to better understand the company's growth potential and product pipeline.
The Long Shadow of Relyvrio's PHOENIX Trial Failure
Despite recent capital raises, the company continues to recover from the failure of its Phase 3 PHOENIX trial for Relyvrio. The drug, intended to treat amyotrophic lateral sclerosis (ALS), failed to show statistically significant benefits in the ALSFRS-R score.
The news of the trial failure caused the stock to plummet more than 80%, falling from $19.00 to a closing price of $3.50 at the time. While some aggressive traders utilize short selling strategies during such collapses, this event was a major setback.
| Before Event | $19.00 |
| After Event | $3.50 |
| Change | -80.00% 🔴 |
| Volume Impact | – |
Following the failure, Leerink Partners downgraded the stock from Outperform to Market Perform. They also slashed their price target from $40.00 to just $5.00, citing concerns about the company's long-term viability.
Is AMLX Stock a Buy, Hold, or Sell Given Recent Volatility?
Investment firms present a balanced but cautious view of Amylyx Pharmaceuticals. The bull case rests on the company's strong cash position, highlighted by a current ratio of 8.72 at the time of its last public offering.
Supporters also point to the $175 million raised to fund the development of Avexitide. However, skeptics remain focused on the loss of Relyvrio's clinical momentum and the potential for the drug's voluntary withdrawal from the market.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • $175M raised for Avexitide | • Phase 3 PHOENIX trial failure |
| • H.C. Wainwright $20.00 price target | • Potential Relyvrio withdrawal risk |
| • Strong current ratio (8.72) | • Leerink Partners $5.00 target |
Investors must weigh the high upside potential noted by H.C. Wainwright against the stark warnings from Leerink Partners. The stock's 252% year-to-date performance for 2026 shows significant recovery, yet it remains sensitive to shifts in clinical sentiment.
What Should Investors Watch Next for Amylyx Pharmaceuticals?
The primary focus for shareholders will be the commercial progress of Avexitide and any updates regarding regulatory discussions for Relyvrio. The company is currently evaluating its next steps with health authorities.
Future earnings reports and updates on research and development spending will be critical. Correctly analyzing a stock requires deep dives into these financial filings to identify potential support levels.
Given that the stock has declined roughly 8% over the last five days, investors are watching for a support level to form. According to analysis from Investing.com, pipeline updates could shift price targets.
The Bottom Line
Amylyx Pharmaceuticals continues to navigate a complex recovery following past clinical setbacks. While today's 3.4% decline lacks an immediate catalyst, it highlights the ongoing sensitivity of the stock to broader sector trends.
With a strong capital position but a fractured product outlook, the company remains a high-risk play in the biotech sector. Investors should monitor upcoming regulatory filings to gauge the company's future trajectory.
